InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,863.34
(
0.83%
)
US TECH 100
19,907.20
(
0.88%
)
Dow Jones
43,070.20
(
0.48%
)
Brent Oil
77.25
(
-0.28%
)
Bitcoin
65,960.61
(
4.95%
)
Post# of 14689
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RoswellChamp

Send PM Follow Ignore
Followers 1
Posts 91
Boards Moderated 0
Alias Born 12/20/2011

RoswellChamp

Re: deadjim post# 4277

Wednesday, 02/12/2014 2:46:43 PM

Wednesday, February 12, 2014 2:46:43 PM

Post# of 14689
The preliminary analysis of the Phase II AE-37 Trial results which they reference in this announcement were quite encouraging. I believe those were available early last Fall. And you are correct about the sample size, 300+ patients is quite large for a Phase II Trial.

The chart is very hard to read, but I have found that my charts are somewhat less than reliable sometimes when dealing with these biotechs, particularly low-priced, speculative ones.....The moves which can be generated---good or bad---by a single piece of news or data can really mess with the tried and true ideas of the charts!
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up